Sotorasib for Vascular Malformations Associated with KRAS G12C Mutation.
N Engl J Med
; 391(4): 334-342, 2024 Jul 25.
Article
em En
| MEDLINE
| ID: mdl-39018528
ABSTRACT
KRAS gain-of-function mutations are frequently observed in sporadic arteriovenous malformations. The mechanisms underlying the progression of such KRAS-driven malformations are still incompletely understood, and no treatments for the condition are approved. Here, we show the effectiveness of sotorasib, a specific KRAS G12C inhibitor, in reducing the volume of vascular malformations and improving survival in two mouse models carrying a mosaic Kras G12C mutation. We then administered sotorasib to two adult patients with severe KRAS G12C-related arteriovenous malformations. Both patients had rapid reductions in symptoms and arteriovenous malformation size. Targeting KRAS G12C appears to be a promising therapeutic approach for patients with KRAS G12C-related vascular malformations. (Funded by the European Research Council and others.).
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Malformações Arteriovenosas
/
Proteínas Proto-Oncogênicas p21(ras)
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article